Difference between revisions of "OTC products for acne treatment"
(→Research Methodology) |
(→Global Acne Medications Market) |
||
(80 intermediate revisions by the same user not shown) | |||
Line 78: | Line 78: | ||
# [http://www.euromonitor.com Euromonmitor International] | # [http://www.euromonitor.com Euromonmitor International] | ||
+ | # [http://www.bccresearch.com BCC Research] | ||
+ | # [http://www.ibisworld.com/ IBISWorld Industry Research] | ||
# [http://www.marketresearch.com MarketResearch.com] | # [http://www.marketresearch.com MarketResearch.com] | ||
# [http://www.frost.com/prod/servlet/frost-home.pag Frost and Sullivan] | # [http://www.frost.com/prod/servlet/frost-home.pag Frost and Sullivan] | ||
Line 89: | Line 91: | ||
# Study covers leading brands for Acne treatment for OTC and not Prescription drugs for mass distribution channel that includes mainstream supermarkets, chain drugstores and mass merchandisers. | # Study covers leading brands for Acne treatment for OTC and not Prescription drugs for mass distribution channel that includes mainstream supermarkets, chain drugstores and mass merchandisers. | ||
− | As per BCC Research | + | =Global Acne Medications Market= |
+ | |||
+ | As per BCC Research the value of the Global Acne Medications Market for year 2012 was estimated to be $3.5 billion and it is expected to reach $4.5 billion by year 2018 at a CAGR of 2.8%. | ||
+ | |||
+ | |||
+ | [[Image:BCC ACNE.jpg|center|thumb|center|632px * 341px|Source:BCC Research,[http://www.marketresearch.com/BCC-Research-v374/Skin-Disease-Treatment-Technologies-Global-7616658]]] | ||
+ | |||
+ | {|border="0" cellspacing="0" cellpadding = "0" width="100%" | ||
+ | |align = "center"|<font color="#282828"><font size = "4">'''The Acne Product Pipeline'''</font></font> | ||
+ | |- | ||
+ | |} | ||
+ | |||
+ | |||
+ | {|border="2" cellspacing="0" cellpadding="4" width="100%" align="center" | ||
+ | |align = "center"|<br>''' ''' '''Product''' | ||
+ | |align = "center"|''' '''<br>'''Company''' | ||
+ | |align = "center"|<br>''' Indication''' | ||
+ | |align = "center"|<br>'''Development Status''' | ||
+ | |- | ||
+ | |ACAT Inhibitor | ||
+ | |Graceway Pharmaceuticals | ||
+ | |Acne | ||
+ | |Phase II | ||
+ | |- | ||
+ | |ANT-1207 (botulinum toxin A) | ||
+ | |Anterios | ||
+ | |Acne vulgaris | ||
+ | |Phase II | ||
+ | |- | ||
+ | |ASC-J9 | ||
+ | |AndroScience | ||
+ | |Acne vulgaris | ||
+ | |Phase II | ||
+ | |- | ||
+ | |AUS-131/doxycycline | ||
+ | |Nexgen Dermatologics | ||
+ | |Acne vulgaris | ||
+ | |Phase I/II | ||
+ | |- | ||
+ | |BLI-1100 | ||
+ | |Braintree Laboratories | ||
+ | |Acne vulgaris | ||
+ | |Phase II | ||
+ | |- | ||
+ | |CD-07223 | ||
+ | |Galderma R &D | ||
+ | |Acne | ||
+ | |Phase II | ||
+ | |- | ||
+ | |CD-2475-101 | ||
+ | |Galderma Laboratories | ||
+ | |Acne vulgaris | ||
+ | |Phase I | ||
+ | |- | ||
+ | |Clindamycin/tretinoin topical combination | ||
+ | |Skinvisible Pharmaceuticals | ||
+ | |Acne | ||
+ | |In clinical trials | ||
+ | |- | ||
+ | |COL-177 | ||
+ | |Onset Dermatologics | ||
+ | |Acne vulgaris | ||
+ | |In clinical trials | ||
+ | |- | ||
+ | |Duac Topical Gel low-dose clindamycin/benzoyl peroxide gel | ||
+ | |Stiefel, a GSK company | ||
+ | |Acne vulgaris | ||
+ | |Application submitted | ||
+ | |- | ||
+ | |E-0301 | ||
+ | |Elorac | ||
+ | |Acne | ||
+ | |Phase III | ||
+ | |- | ||
+ | |IDP 107 | ||
+ | |Valeant Pharmaceuticals | ||
+ | |Acne vulgaris | ||
+ | |Phase II | ||
+ | |- | ||
+ | |Isotretinoin | ||
+ | |Cipher Pharmaceuticals | ||
+ | |Acne | ||
+ | |Phase III | ||
+ | |- | ||
+ | |JNJ-10229570 | ||
+ | |Johnson & Johnson | ||
+ | |Acne vulgaris | ||
+ | |Phase II | ||
+ | |- | ||
+ | |Metvixia | ||
+ | |PhotoCure methyl aminolevulinate | ||
+ | |Acne | ||
+ | |Phase II | ||
+ | |- | ||
+ | |NB-003 (nanoemulsion) | ||
+ | |NanoBio | ||
+ | |Acne | ||
+ | |Phase I | ||
+ | |- | ||
+ | |NVC-422 | ||
+ | |Galderma | ||
+ | |Acne | ||
+ | |Phase I completed | ||
+ | |- | ||
+ | |Tazarotene foam (retinoid foam) | ||
+ | |Stiefel, a GSK company | ||
+ | |Acne vulgaris | ||
+ | |Phase III | ||
+ | |- | ||
+ | |Tretinoin topical | ||
+ | |Phosphagenics | ||
+ | |Acne | ||
+ | |Phase I | ||
+ | |- | ||
+ | |WC-3018 | ||
+ | |Warner Chilcott | ||
+ | |Acne | ||
+ | |Phase II | ||
+ | |- | ||
+ | |WC-3035 | ||
+ | |Warner Chilcott | ||
+ | |Acne | ||
+ | |Phase I | ||
+ | |- | ||
+ | |}<br clear="all"> | ||
+ | |||
+ | {|border="0" cellspacing="0" cellpadding = "0" width="100%" | ||
+ | |<font color="#282828"> Source: [http://www.phrma.org/sites/default/files/pdf/skindiseases2011.pdf Pharmaceutical Research and Manufacturers of America, 2011] | ||
− | |||
== '''USA market study''' == | == '''USA market study''' == | ||
Line 97: | Line 225: | ||
===Historic Sales=== | ===Historic Sales=== | ||
− | * The Acne Treatment Manufacturing OTC industry has maintained strong growth during the past five years. | + | * The Acne Treatment Manufacturing OTC industry has maintained strong growth during the past five years. As per IBIS World estimates from 2007 to 2012, revenue has grown steady, and it is expected to grow at an average annual rate of 2.4% to $2.3 billion. |
− | * Because acne-prone individuals consider treatment products a necessary expense, revenue continued to rise during the recession, though growth did slow as consumers switched to more inexpensive products. | + | * Because acne-prone individuals consider treatment products a necessary expense, revenue continued to rise during the recession, though growth did slow as consumers switched to more inexpensive products. |
− | * . In 2012, industry revenue is expected to maintain its growth, gaining 2.7% during the year, due to modest improvements in per capita disposable income. | + | * Increasing prevalence of adult-onset and persistent acne conditions has given rise to new, targeted products and an expanded consumer base, another factor that has aided revenue growth during the period. |
+ | |||
+ | * In 2012, industry revenue is expected to maintain its growth, gaining 2.7% during the year, due to modest improvements in per capita disposable income. | ||
− | |||
− | + | [[Image:USACNE2012.jpg|center|thumb|center|632px * 341px|Source:IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]] | |
− | + | ||
+ | ===Industry Forecast=== | ||
− | + | * From 2012 to 2017, industry revenue is expected to go up an annualized rate of 3.1% to $2.7 billion from current level of $2.3 billion. | |
+ | * Improving economic conditions is likely to drive the market, as greater disposable income growth allows consumers to spend on higher-priced over-the-counter (OTC) items. | ||
− | |||
− | + | [[Image:US2018 acne.jpg|center|thumb|center|632px * 341px|Source:IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]] | |
− | + | ===Major Players in Acne Space=== | |
− | + | * As per IBIS World estimates the top three industry players (Johnson & Johnson, Guthy-Renker and Reckitt-Benckiser) hold a combined market share of about 68.1%, in 2012. The rest of the market is characterized by a large number of small and medium-size businesses. | |
− | + | ||
− | + | ||
− | * | + | * J&J (Neutrogena, Clean & Clear, Aveeno, Ambi) commanded over 28.8% of anti-acne preparation sales in 2012. J&J’s closest rival was Guthy Renker,(Proactiv Solutions) which had a 24.6% share followed by Reckitt Benckiser at 14.7%. |
− | + | ||
− | + | ||
− | + | ||
− | [[Image: | + | [[Image:US Acne Share.jpg|US Acne Share.jpg|thumb|center|632px * 341px|Source:IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]] |
===Consumer Target Group & Product Categorization=== | ===Consumer Target Group & Product Categorization=== |
Latest revision as of 05:00, 17 October 2013
Contents
Objective
A global understanding of markets, products, and distribution channels related to the acne product market. Our overall focus is on the OTC market, not prescription.
Introduction
Definition
Acne vulgaris (commonly called acne) is a common skin condition, affecting 85-100% of people at some time during their lives. It is caused by changes in the pilosebaceous units, skin structures consisting of a hair follicle and its associated sebaceous gland. It is characterized by noninflammatory follicular papules or comedones and by inflammatory papules, pustules, and nodules in its more severe forms. Acne vulgaris affects the areas of skin with the densest population of sebaceous follicles; these areas include the face, the upper part of the chest, and the back. Severe acne is inflammatory, but acne can also manifest in noninflammatory forms. Acne lesions are commonly referred to as pimples, blemishes, spots, zits, or acne. Source
There's been a gap in products marketed to adult women--little or nothing was available to address their acne needs, and as a result, sales have lagged. "No one was looking to target the 30- to 40-year-olds," said Lee Feldman, vice president of sales for Advanced Research Labs. Source
- In this report we have presented Acne Market details for following countries.
Causes of Acne
Acne is a common occurrence at puberty. With the increased production of sex hormones, the sebaceous glands become hyperactive. Androgen and progesterone are responsible for the hyperplasia of the oil glands. The usual premenstrual flare-up is explained by some observers as occurring during the period when the normal androgen-estrogen balance in the blood is altered in favor of androgen. Hence hormonal imbalance is held responsible for causing acne. Psychogenic stresses particularly the habit of picking pimples, makes them worse.
Besides seborrhoeic diathesis and hormonal imbalance, other factors which aggravate acne are:
- a diet rich in fats and starches;
- intestinal stasis, especially constipation;
- a sedentary life;
- excessive use of greasy cosmetics, pomade, detergents and mechanical rubbing
- Heavy or oily make up
- Over abrasive cleansing
- Diet high in nutritious food can also help aggravate acne.
Acne Types
There are various types of acne and they are:-
- Acne Rosacea
- Acne Cosmetica
- Acne Vulgaris
- Acne Fulminans
- Acne Keloidalis Nuchae
- Acne Chloracne
- Acne Medicamentosa
Acne Treatment
Medical Treatment
Medical treatment is suggested only in cases of chronic or severe acne and should be taken from the dermatologist.
To outline the drug treatment, it aims chiefly to:
- Cut down the bacteria in the hair follicles and on the skin surface.
- Open the hair follicles by removal of the blackheads.
- Cut down the acne inflammations.
Local Drug Treatments
Benzoyl Peroxide preparations available as gels and lotions have become very popular in the treatment of acne. Cream "Ultra Clearasil" is a very potent Benzoyl preparation. One of the main action points of Benzoyl Peroxide is to kill bacteria. It releases oxygen which helps in killing aerobic bacteria.
The sulphur drug preparations, available as creams, gels and lotions, are extremely effective in treating acne. Like Benzoyl Peroxide, sulphur is committed to killing bacteria. Sulphur is a disinfectant and used in skin treatments for eczema, etc.
Tetracycline usually has no side-effects and hence is the safest drug. However, in some uncommon cases, it causes bilousness, indigestion, vaginal thrush or rash.
Research Methodology
Objective A global understanding of markets, products, and distribution channels related to the acne product market. Our overall focus is on the OTC market(Excluding prescription drugs).
Data Collection
Secondary data sources are only used to conduct the research.
The list of various sources used to conduct the research are as follows:
- Euromonmitor International
- BCC Research
- IBISWorld Industry Research
- MarketResearch.com
- Frost and Sullivan
- Marketline Business Information Center (Datamonitor)
- Online Pharmacy Store: drugstore.com
- Search Engine: Google
Scope of the study
- Included two major markets namely U S and Japan.
- Study covers leading brands for Acne treatment for OTC and not Prescription drugs for mass distribution channel that includes mainstream supermarkets, chain drugstores and mass merchandisers.
Global Acne Medications Market
As per BCC Research the value of the Global Acne Medications Market for year 2012 was estimated to be $3.5 billion and it is expected to reach $4.5 billion by year 2018 at a CAGR of 2.8%.
![](/wiki/images/thumb/BCC_ACNE.jpg/180px-BCC_ACNE.jpg)
The Acne Product Pipeline |
Product |
Company |
Indication |
Development Status |
ACAT Inhibitor | Graceway Pharmaceuticals | Acne | Phase II |
ANT-1207 (botulinum toxin A) | Anterios | Acne vulgaris | Phase II |
ASC-J9 | AndroScience | Acne vulgaris | Phase II |
AUS-131/doxycycline | Nexgen Dermatologics | Acne vulgaris | Phase I/II |
BLI-1100 | Braintree Laboratories | Acne vulgaris | Phase II |
CD-07223 | Galderma R &D | Acne | Phase II |
CD-2475-101 | Galderma Laboratories | Acne vulgaris | Phase I |
Clindamycin/tretinoin topical combination | Skinvisible Pharmaceuticals | Acne | In clinical trials |
COL-177 | Onset Dermatologics | Acne vulgaris | In clinical trials |
Duac Topical Gel low-dose clindamycin/benzoyl peroxide gel | Stiefel, a GSK company | Acne vulgaris | Application submitted |
E-0301 | Elorac | Acne | Phase III |
IDP 107 | Valeant Pharmaceuticals | Acne vulgaris | Phase II |
Isotretinoin | Cipher Pharmaceuticals | Acne | Phase III |
JNJ-10229570 | Johnson & Johnson | Acne vulgaris | Phase II |
Metvixia | PhotoCure methyl aminolevulinate | Acne | Phase II |
NB-003 (nanoemulsion) | NanoBio | Acne | Phase I |
NVC-422 | Galderma | Acne | Phase I completed |
Tazarotene foam (retinoid foam) | Stiefel, a GSK company | Acne vulgaris | Phase III |
Tretinoin topical | Phosphagenics | Acne | Phase I |
WC-3018 | Warner Chilcott | Acne | Phase II |
WC-3035 | Warner Chilcott | Acne | Phase I |
Source: Pharmaceutical Research and Manufacturers of America, 2011
USA market studyHistoric Sales
![]() Source:IBIS World,[2] Industry Forecast
![]() Source:IBIS World,[3] Major Players in Acne Space
![]() Source:IBIS World,[4] Consumer Target Group & Product CategorizationConsumer Target Group Here we have divided entire population into various categories. This categories are defined as follows:
Product Categorization Here, we had tried to categorize the the different products under following 3 categories.
The below information is regarding the target group and categories are obtained from company websites and review published on various online pharmacy sites.
OTC ProductsThis report covers the product available in mass distribution channel only. Product DashboardSnapshot of the dashboard
Japan Market StudyMarket Facts
Historic SalesFollowing figure shows the sales of acne treatment product during the period 2004 to 2007. Brands and their Sales
[Source : Euromonitor International] Categorization of Products
Sales Forecast
Like this report? This is only a sample report with brief analysis
Contact Dolcera
|